Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-138810

Published: 2020

Journal Articles

CITED2 Affects Leukemic Cell Survival By Interfering with p53 Activation

Katharina Mattes, MSc, Gerbrig Berger, BSc, Marjan Geugien, MSc, Joost H.A. Martens, Edo Vellenga, MD PhD, Hein Schepers, PhD

Blood (2016) 128 (22): 1542.

https://doi.org/10.1182/blood.V128.22.1542.1542

Published: 2016

Journal Articles

Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT

Blood (2016) 128 (22): 3467.

https://doi.org/10.1182/blood.V128.22.3467.3467

Published: 2016

Journal Articles

Following Autologous Stem Cell Transplantation (1 Yr) Mesenchymal Stem Cells Are Functionally Impaired with Reduced Hematopoietic Support

Catharina Hazenberg, MD, Fiona A.J. van den Heuvel, Edo Vellenga, MD PhD, Annet Z. Brouwers-Vos, Gerbrig Berger, BSc, Jan Jacob Schuringa, PhD

Blood (2016) 128 (22): 3888.

https://doi.org/10.1182/blood.V128.22.3888.3888

Published: 2016

Journal Articles

RUNX1 Mutations Cause a Myeloid Differentiation Block Leading to the Formation of a Long Term Expanding CD34 + /CD33 + /CD45RA + /CD123 + Cell Population

Myléne Gerritsen, MSc, Esther Tijchon, PhD, Amit Mandoli, PhD, Joost H.A. Martens, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2016) 128 (22): 1979.

https://doi.org/10.1182/blood.V128.22.1979.1979

Published: 2016

Journal Articles

Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10)

Blood (2016) 128 (22): 224.

https://doi.org/10.1182/blood.V128.22.224.224

Published: 2016

Journal Articles

Blocking the Autophagy Pathway As Potential Target for the Treatment of Wild Type P53 AMLs

Hendrik Folkerts, MSc, Susan Hilgendorf, MSc, Albertus T. Wierenga, PhD, Paul J. Coffer, PhD, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2016) 128 (22): 770.

https://doi.org/10.1182/blood.V128.22.770.770

Published: 2016

Journal Articles

Targeting Autophagy As a Potential Therapeutic Strategy for the Treatment of AML

Hendrik Folkerts, MSc, Bart-Jan A.T.J. Wierenga, PhD, Paul J. Coffer, PhD, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2015) 126 (23): 3831.

https://doi.org/10.1182/blood.V126.23.3831.3831

Published: 2015

Journal Articles

CITED2 Cooperates with Low PU.1 and DNMT3A to Maintain Self-Renewal in Hematopoietic Stem Cells

Hein Schepers, PhD, Patrick Korthuis, MSc, Marjan Geugien, MSc, Jennifer Jaques, MSc, Tihomira I. Todorova, MSc, Ulrich Steidl, MD PhD, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2015) 126 (23): 309.

https://doi.org/10.1182/blood.V126.23.309.309

Published: 2015

Journal Articles

Loss of ASXL1 Triggers an Apoptotic Response in Human Hematopoietic Stem and Progenitor Cells

Susan Hilgendorf, MSc, Hendrik Folkerts, MSc, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2015) 126 (23): 4107.

https://doi.org/10.1182/blood.V126.23.4107.4107

Published: 2015

Journal Articles

Loss of ASXL1 Triggers an Apoptotic Response in Human Hematopoetic Stem and Progenitor Cells

Susan Hilgendorf, Hendrik Folkerts, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2014) 124 (21): 4619.

https://doi.org/10.1182/blood.V124.21.4619.4619

Published: 2014

Journal Articles

Combined Treatment of Bortezomib, Continuous Low-Dose Cyclophosphamide and Dexamethasone Followed By One Year of Maintenance Treatment for Refractory or Relapsed Multiple Myeloma Patients: A Prospective Phase II Study

Esther GM Waal de, MD, Linda Munck de, Gerhard Woolthuis, MD, Annet velden Van Der, MD, Yvonne Tromp, MD, Mels Hoogendoorn, MD PhD, Edo Vellenga, MD PhD, Sjoerd Hovenga, MDPhD

Blood (2014) 124 (21): 4733.

https://doi.org/10.1182/blood.V124.21.4733.4733

Published: 2014

Journal Articles

ATG5 and ATG7 Fulfill Essential and Non-Redundant Roles in Human Hematopoietic Stem/Progenitor Cells

Hendrik Folkerts, Maria Catalina Gomez Puerto, Albertus T.J. Wierenga, PhD, Koen Schepers, PhD, Jan Jacob Schuringa, PhD, Paul J. Coffer, PhD BA, Edo Vellenga, MD PhD

Blood (2014) 124 (21): 4316.

https://doi.org/10.1182/blood.V124.21.4316.4316

Published: 2014

Journal Articles

Mesenchymal Stem Cells from Patients 1 Year Following Autologous Stem Cell Transplantation Have a Pro-Inflammatory and Senescent Phenotype Compromising the Support of Hematopoietic Stem Cells

Carin L.E. Hazenberg, MD, Fiona A.J. van den Heuvel, Ben N.G. Giepmans, PhD, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD

Blood (2014) 124 (21): 4368.

https://doi.org/10.1182/blood.V124.21.4368.4368

Published: 2014

Journal Articles

Evaluation of Extrinsic and Intrinsic Cues Involved in BCR-ABL-Induced Leukemogenesis

Pallavi Suhas Sontakke, MSC, Richard W.J. Groen, PhD, Katarzyna Koczula, MSC, Jennifer Jaques, Huipin Yuan, PhD, Ulrich Günther, PhD, Anton C. Martens, PhD, Edo Vellenga, MD PhD, Jan J. Schuringa, PhD

Blood (2014) 124 (21): 515.

https://doi.org/10.1182/blood.V124.21.515.515

Published: 2014

Journal Articles

Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network

Pieter Sonneveld, MDPhD, Emilie Asselbergs, Bronno Van der Holt, PhD, Sonja Zweegman, MDPhD, Marie jose Kerstens, MD, Edo Vellenga, MD PhD, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk Lokhorst

Blood (2014) 124 (21): 2118.

https://doi.org/10.1182/blood.V124.21.2118.2118

Published: 2014

Journal Articles

Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Blood (2013) 122 (21): 2731.

https://doi.org/10.1182/blood.V122.21.2731.2731

Published: 2013

Journal Articles

Convergence Of Hypoxia and TGFβ Pathways On Cell Cycle Regulation In Human Hematopoietic Stem/Progenitor Cells

Albertus T.J. Wierenga, PhD, Edo Vellenga, MD, PhD, Jan Jacob Schuringa, PhD

Blood (2013) 122 (21): 3694.

https://doi.org/10.1182/blood.V122.21.3694.3694

Published: 2013

Journal Articles

Establishing Human Niche Xenograft Models For Myeloid and Lymphoid Leukemia Driven By MLL-AF9

Marco Carretta, Jennifer Jaques, Yuan Huipin, Anton Martens, PhD, Edo Vellenga, MD, PhD, Richard Groen, Jan Jacob Schuringa, PhD

Blood (2013) 122 (21): 1646.

https://doi.org/10.1182/blood.V122.21.1646.1646

Published: 2013

Journal Articles

Validation Of a Multi-Diagnostic Approach Including Flow Cytometry To Identify Specific Risk Categories Within Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Eline M.P. Cremers, MD, Theresia M. Westers, PhD, Canan Alhan, MD, Claudia Cali, Heleen A. Visser-Wisselaar, PhD, Dana A Chitu, PhD, Marian J.P.L. Stevens-Kroef, PhD, Pedro Silva Coelho, MD, Edo Vellenga, MD, PhD, Saskia K. Klein, MD PhD, Pierre W. Wijermans, MD, PhD, Georgine E. de Greef, MD, PhD, Martijn R. Schaafsma, MD, PhD, M Marwijk Kooy, MD, PhD, Petra Muus, MD, PhD, Gert J. Ossenkoppele, MD PhD, Joop H. Jansen, PhD, Arjan A. van de Loosdrecht, MD, PhD

Blood (2013) 122 (21): 1521.

https://doi.org/10.1182/blood.V122.21.1521.1521

Published: 2013

NARROW

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

CITED2 Affects Leukemic Cell Survival By Interfering with p53 Activation

Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT

Following Autologous Stem Cell Transplantation (1 Yr) Mesenchymal Stem Cells Are Functionally Impaired with Reduced Hematopoietic Support

RUNX1 Mutations Cause a Myeloid Differentiation Block Leading to the Formation of a Long Term Expanding CD34 + /CD33 + /CD45RA + /CD123 + Cell Population

Blocking the Autophagy Pathway As Potential Target for the Treatment of Wild Type P53 AMLs

Targeting Autophagy As a Potential Therapeutic Strategy for the Treatment of AML

CITED2 Cooperates with Low PU.1 and DNMT3A to Maintain Self-Renewal in Hematopoietic Stem Cells

Loss of ASXL1 Triggers an Apoptotic Response in Human Hematopoietic Stem and Progenitor Cells

Loss of ASXL1 Triggers an Apoptotic Response in Human Hematopoetic Stem and Progenitor Cells

Combined Treatment of Bortezomib, Continuous Low-Dose Cyclophosphamide and Dexamethasone Followed By One Year of Maintenance Treatment for Refractory or Relapsed Multiple Myeloma Patients: A Prospective Phase II Study

ATG5 and ATG7 Fulfill Essential and Non-Redundant Roles in Human Hematopoietic Stem/Progenitor Cells

Mesenchymal Stem Cells from Patients 1 Year Following Autologous Stem Cell Transplantation Have a Pro-Inflammatory and Senescent Phenotype Compromising the Support of Hematopoietic Stem Cells

Evaluation of Extrinsic and Intrinsic Cues Involved in BCR-ABL-Induced Leukemogenesis

Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network

Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Convergence Of Hypoxia and TGFβ Pathways On Cell Cycle Regulation In Human Hematopoietic Stem/Progenitor Cells

Establishing Human Niche Xenograft Models For Myeloid and Lymphoid Leukemia Driven By MLL-AF9

Validation Of a Multi-Diagnostic Approach Including Flow Cytometry To Identify Specific Risk Categories Within Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only